GlassScriptPhysician profile
Matthew J Eich
NPI 1306487855
$8,423.91
in general payments reported to CMS, 2019-2025
29 companies · $464 in 2025
The $464 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $530 · 2022: $2,613 · 2023: $2,601 · 2024: $2,216 · 2025: $464.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,239 · Education: $42.75.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,238.97 |
| Education | $42.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,809.27 | 2021-2025 | Stelara, Tremfya |
| Abbvie INC. | $1,715.42 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,091.40 | 2021-2025 | Xifaxan, Trulance, Plenvu |
| Takeda Pharmaceuticals U.S.A., INC. | $688.56 | 2022-2025 | Entyvio, Eohilia, Gattex |
| Qol Medical, LLC | $449.84 | 2022-2024 | Sucraid, Sucraid |
| Celgene Corporation | $399.16 | 2022-2024 | Zeposia |
| Pfizer INC. | $391.99 | 2021-2024 | |
| Janssen Scientific Affairs, LLC | $257.44 | 2021-2023 | Stelara |
| Phathom Pharmaceuticals, INC. | $186.07 | 2024 | Voquezna |
| Ardelyx, INC. | $181.74 | 2023-2024 | Ibsrela |
| Regeneron Healthcare Solutions, INC. | $177.45 | 2022-2025 | Dupixent |
| Alfasigma USA, INC. | $161.60 | 2022 | |
| Braintree Laboratories, INC. | $142.36 | 2022-2025 | Sutab, Suflave |
| Ironwood Pharmaceuticals, INC | $96.23 | 2022-2024 | Linzess |
| Intercept Pharmaceuticals, INC. | $93.29 | 2023-2024 | Ocaliva |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $80.69 | 2024-2025 | Vowst |
| Nestle Healthcare Nutrition INC. | $75.76 | 2022-2023 | |
| Celltrion USA INC. | $67.19 | 2023-2024 | Zymfentra, Yuflyma |
| Lilly USA, LLC | $60.65 | 2024-2025 | Omvoh |
| Ferring Pharmaceuticals INC. | $50.94 | 2021-2023 | Rebyota, Cimzia |
| Genzyme Corporation | $46.96 | 2023-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.81 | 2023 | Cyltezo |
| Merck Sharp & Dohme LLC | $34.15 | 2023 | Dificid |
| Amgen INC. | $33.52 | 2023 | Avsola, Amjevita |
| Alnylam Pharmaceuticals INC. | $27.93 | 2023 | Onpattro |
| Gilead Sciences, INC. | $26.38 | 2024 | |
| Mallinckrodt Hospital Products INC. | $17.32 | 2022 | |
| Daiichi Sankyo INC. | $13.31 | 2022 | |
| Janssen Pharmaceuticals, INC | $10.48 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Eich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.